New Drug Development Services
Host vs graft (HVG)
Welcome to learn about our Host Anti-Graft Reaction (HVG) evaluation platform. We are committed to providing comprehensive and in-depth immunogenicity assessments for allogeneic cell therapies.
Platform Features and Applications:
•Next Generation iHuPBMC Platform by Chuangmo BiotechWe utilize Chuangmo Biotech's next generation iHuPBMC platform, which achieves a comprehensive reconstruction of the human immune system. This technology provides us with a model that closely resembles the true human environment.Model, allowing us to more accurately assess the effects of allogeneic cell therapies.
•In-depth Immunogenicity Assessment: Using our platform, we can conduct in-depth assessments of the immunogenicity of allogeneic cell therapies, understanding how therapeutic cells interact with the host's immune system.
•Assessment of Rejection Reactions: Our evaluation platform can also assess the potential rejection reactions of the recipient to therapeutic cells, providing critical data support for your cell therapy research.
Our Host Anti-Graft Reaction (HVG) evaluation platform combines advanced technology and in-depth research to provide comprehensive support for your cell therapy research and product development. If you have any questions or need further information, please feel free to Contact Us.
HVG Testing Platform Based on PBMC-T/NK Reconstruction
Using PBMC immune system humanized mice, we validate the host anti-graft (HVG) effects of the tested U-Car and CAR-T, examining their retention ability in patients against attacks from the patient's immune system.
After the infusion of CAR-T cells, human lymphocytes deplete due to attacking CAR-T cells, resulting in a downward curve. Mouse-derived lymphocytes lose suppression from human lymphocytes and rebound. After the infusion of U-CAR cells, human lymphocytes do not attack U-CAR cells, thus continuing to suppress mouse-derived lymphocytes.